药物涂层球囊治疗急性冠状动脉综合征的疗效。

IF 1.8 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Research and Practice Pub Date : 2023-04-20 eCollection Date: 2023-01-01 DOI:10.1155/2023/4594818

Hirokazu Naganawa, Akira Ito, Shinrou Saiki, Daisuke Nishi, Shinichi Takamatsu, Yoshihisa Ito, Takeshi Suzuki

{"title":"药物涂层球囊治疗急性冠状动脉综合征的疗效。","authors":"Hirokazu Naganawa, Akira Ito, Shinrou Saiki, Daisuke Nishi, Shinichi Takamatsu, Yoshihisa Ito, Takeshi Suzuki","doi":"10.1155/2023/4594818","DOIUrl":null,"url":null,"abstract":"Background: Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS.Materials and methods: In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year.Results: Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73).Conclusions: DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139813/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome.\",\"authors\":\"Hirokazu Naganawa, Akira Ito, Shinrou Saiki, Daisuke Nishi, Shinichi Takamatsu, Yoshihisa Ito, Takeshi Suzuki\",\"doi\":\"10.1155/2023/4594818\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS.Materials and methods: In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year.Results: Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73).Conclusions: DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.\",\"PeriodicalId\":9494,\"journal\":{\"name\":\"Cardiology Research and Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139813/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiology Research and Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/4594818\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/4594818","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

背景：使用药物洗脱支架（DES）进行经皮冠状动脉介入治疗是急性冠状动脉综合征（ACS）的常见治疗方法。然而，支架相关并发症依然存在，如与双重抗血小板疗法相关的出血、支架内再狭窄、支架血栓和新动脉硬化。药物涂层球囊（DCB）有望减少支架相关并发症。本研究旨在评估DCB疗法的疗效，并将其与ACS患者的DES疗法进行比较：在这项单中心、回顾性、观察性研究中，我们检查了2014年7月至2020年11月期间接受DCB或DES治疗的所有ACS患者。排除了左主干病变患者。主要结果是一年后主要不良心血管事件（MACE：心源性死亡、心肌梗死和靶病变血管再通）的复合结果：结果：372名患者接受了DES治疗，83名患者接受了DCB治疗。DCB组有10例（12.0%）患者发生MACE，DES组有50例（13.4%）患者发生MACE（P=0.73）：结论：DCB对ACS患者是一种有价值且有效的治疗方法。结论：对 ACS 患者而言，DCB 是一种有价值且有效的疗法，而且 DCB 可能成为 ACS 患者 DES 的替代疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome.

Background: Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS.

Materials and methods: In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year.

Results: Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73).

Conclusions: DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cardiology Research and Practice Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Cardiology Research and Practice is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies that focus on the diagnosis and treatment of cardiovascular disease. The journal welcomes submissions related to systemic hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease, and cardiomyopathy.